CNS Efficacy and Distant Metastases Outcomes of Osimertinib After Definitive Chemoradiotherapy in Patients With Unresectable Stage III EGFR-Mutated NSCLC
Sign in to PracticeUpdate
Only registered members have full access to PracticeUpdate content.
Additional Info
Annals of Oncology
From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine.
Osimertinib after definitive chemoradiotherapy in unresectable stage III epidermal growth factor receptor-mutated non-small-cell lung cancer: analyses of central nervous system efficacy and distant progression from the phase III LAURA study
Ann. Oncol 2024 Sep 11;[EPub Ahead of Print], S Lu, MJ Ahn, T Reungwetwattana, M Özgüroğlu, T Kato, JC Yang, M Huang, F Fujiki, T Inoue, LV Quang, V Sriuranpong, D Vicente, C Fuentes, AA Chaudhry, L Poole, E Armenteros Monterroso, Y Rukazenkov, T van der Gronde, SS RamalingamFrom MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine.